Autolus Therapeutics Ltd (NASDAQ:AUTL) — Market Cap & Net Worth
Market Cap & Net Worth: Autolus Therapeutics Ltd (AUTL)
Autolus Therapeutics Ltd (NASDAQ:AUTL) has a market capitalization of $503.01 Million ($503.01 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12236 globally and #3073 in its home market, demonstrating a -15.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Autolus Therapeutics Ltd's stock price $1.89 by its total outstanding shares 266143286 (266.14 Million). Also see Autolus Therapeutics Ltd assets under control for a full breakdown of the balance sheet.
Autolus Therapeutics Ltd Market Cap History: 2018 to 2026
Autolus Therapeutics Ltd's market capitalization history from 2018 to 2026. Data shows change from $8.74 Billion to $503.01 Million (-26.91% CAGR). Also see Autolus Therapeutics Ltd (AUTL) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Autolus Therapeutics Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.02% | #339 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #1224 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.03% | #189 of 263 |
Weight: Autolus Therapeutics Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Autolus Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Autolus Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Autolus Therapeutics Ltd stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
7.01x
Autolus Therapeutics Ltd's market cap is 7.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $8.74 Billion | $1.05 Million | -$31.11 Million | 8361.03x | N/A |
| 2018 | $8.74 Billion | $1.05 Million | -$31.11 Million | 8361.03x | N/A |
| 2019 | $3.51 Billion | $2.91 Million | -$123.85 Million | 1208.08x | N/A |
| 2020 | $2.38 Billion | $1.72 Million | -$142.09 Million | 1387.36x | N/A |
| 2021 | $1.38 Billion | $1.51 Million | -$142.10 Million | 916.58x | N/A |
| 2022 | $505.67 Million | $6.19 Million | -$148.84 Million | 81.64x | N/A |
| 2023 | $1.71 Billion | $1.70 Million | -$208.38 Million | 1009.40x | N/A |
| 2024 | $625.44 Million | $10.12 Million | -$220.66 Million | 61.80x | N/A |
| 2025 | $529.63 Million | $75.56 Million | -$288.20 Million | 7.01x | N/A |
Competitor Companies of AUTL by Market Capitalization
Companies near Autolus Therapeutics Ltd in the global market cap rankings as of September 17, 2026. Review AUTL intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Autolus Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Autolus Therapeutics Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Autolus Therapeutics Ltd's market cap moved from $8.74 Billion to $ 503.01 Million, with a yearly change of -26.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $503.01 Million | -5.03% |
| 2025 | $529.63 Million | -15.32% |
| 2024 | $625.44 Million | -63.51% |
| 2023 | $1.71 Billion | +238.95% |
| 2022 | $505.67 Million | -63.39% |
| 2021 | $1.38 Billion | -41.95% |
| 2020 | $2.38 Billion | -32.27% |
| 2019 | $3.51 Billion | -59.81% |
| 2018 | $8.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Autolus Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $503.01 Million USD |
| MoneyControl | $503.01 Million USD |
| MarketWatch | $503.01 Million USD |
| marketcap.company | $503.01 Million USD |
| Reuters | $503.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more